Health Catalyst (HCAT), a healthcare data analytics company focused on helping health systems improve outcomes and financial performance, will report fourth-quarter results this Thursday after the market closes. With the stock down sharply over the past month and investor confidence still fragile, this print is less about “beat or miss” optics and more about whether the company can show a credible path to stabilizing growth and rebuilding momentum after a guidance stumble last quarter.
In the previous quarter, Health Catalyst beat revenue expectations with $76.32 million in sales, essentially flat year over year. But the quarter was described as slower, and what really rattled the market was forward-looking commentary: revenue guidance for the next quarter missed analysts’ expectations significantly, and EBITDA guidance also came in well below what Wall Street was modeling. In other words, the report had the classic profile investors hate: the past looked acceptable, but the future looked foggy.
Now, heading into Q4, the market is expecting revenue to decline 7% year over year, a reversal from the 6% growth the company posted in the same quarter last year. Analysts have generally reconfirmed their estimates over the last 30 days, which often signals that expectations are set—and that the bar for a positive surprise may be clearer than usual.
Below is what matters most in this report, and what could move the stock next.
The setup: a confidence problem, not just a quarter problem
Health Catalyst is heading into earnings with weak price action and a skeptical audience. Shares are down about 15.5% over the last month, while the broader data analytics peer group has been roughly flat. That divergence tells you the market is not punishing “analytics” broadly—it’s punishing uncertainty around HCAT’s execution and trajectory.
At the same time, the average analyst price target cited is $3.88 versus a recent share price around $1.83, implying analysts still see substantial upside if the company can stabilize. That gap is a double-edged sword: it can attract contrarian buyers, but it also highlights how far expectations have fallen.
So, what does the company need to prove?
1) Revenue trajectory: is the decline temporary or structural?
With the market pricing a 7% year-over-year revenue decline, the first question is straightforward: does the quarter confirm deceleration, or does it show the business is holding up better than feared?
For Health Catalyst, the more important story may be the composition and durability of revenue rather than the headline number:
- Recurring vs. services mix: Investors typically reward software-like recurring revenue streams and penalize lumpy professional services. If the company can show recurring revenue resilience—even while total revenue dips—that can matter for valuation and sentiment.
- Customer expansion behavior: In healthcare enterprise software, retention may remain stable even when expansions slow. A “pause” in expansions can look like a growth reset, but it can also be cyclical budgeting friction. The report needs to clarify which one it is.
A mild miss might not be fatal if management can credibly frame the decline as transitory and show improving indicators in pipeline and renewals. But if the quarter confirms broad softness across both new business and expansions, the market may treat it as a structural slowdown.
2) Guidance: the biggest swing factor in the report
Because the prior quarter’s weakness was largely a guidance shock, forward guidance will likely be the primary driver this time as well.
Investors will look for:
- Next-quarter revenue guidance vs. current expectations: The company doesn’t need to deliver a moonshot forecast. It needs to avoid another “surprise gap” that forces the Street to cut numbers again.
- EBITDA guidance and profitability narrative: Last quarter’s EBITDA guidance miss raised questions about cost structure and the pace of operating leverage. If the company indicates that margin pressure persists, the market may assume more dilution risk (raising capital) or prolonged losses.
- Any signal of re-acceleration: Even modest language suggesting improving sales cycle conversion, stronger bookings, or pipeline rebuild can shift the narrative—if supported with real metrics.
If guidance stabilizes and comes in closer to consensus, that alone could be interpreted as a “less bad” inflection point. In beaten-down stocks, “not getting worse” can sometimes be enough to spark a relief move.
3) Bookings, backlog, and pipeline: the hidden heartbeat of the quarter
Revenue in enterprise healthcare analytics often lags bookings. That means the market will obsess over the indicators that hint at what revenue might look like two to four quarters out.
The company’s report and call will likely be mined for:
- Bookings growth (or contraction)
- Lengthening or shortening of sales cycles
- Pipeline coverage into the next two quarters
- Renewals and expansions
- Any commentary on hospital spending behavior and budgeting cycles
Hospitals and health systems are notorious for cautious tech spending environments when there’s uncertainty around reimbursement, labor costs, or broader macro conditions. If management describes delayed decisions rather than lost deals, investors may treat the softness as timing-driven. But if the commentary points to cancellations, downsizing, or competitive displacement, the market reaction could be harsher.
4) Customer metrics: retention, churn, and net revenue retention
For subscription-style models, net revenue retention (NRR) and churn trends are often more informative than top-line growth in any one quarter.
Even if overall revenue is down year over year, investors can remain constructive if they see:
- churn is contained,
- customers are still renewing at healthy rates,
- expansions are muted but not broken,
- and the company is landing meaningful new logos.
If retention metrics are weakening, that’s a more serious signal: it implies the value proposition may be under pressure or competition is intensifying.
5) Competitive context: what peers tell us (and what they don’t)
The data analytics segment is delivering mixed signals. Some peers have shown strong performance:
- Palantir Technologies delivered 70% year-over-year revenue growth, beating expectations, and the stock rose after results.
- Strategy reported revenue growth of 1.9%, also beating expectations, and the stock surged.
Those are not perfect comps—Palantir’s growth profile is unique and Strategy’s business model is not a clean “analytics SaaS” peer. Still, the takeaway is that investors are willing to reward analytics narratives when growth and conviction are strong.
For Health Catalyst, this makes execution more important: the market is not in a mood to excuse underdelivery just because “tech is hard.” If peers can print strength, HCAT’s softness looks more company-specific.
6) What could surprise the market positively?
Given the stock’s depressed level and negative recent momentum, a positive surprise doesn’t require perfection. Here are the upside catalysts investors will watch for:
- Revenue holds up better than feared (less than a 7% decline, or flat).
- Guidance comes in meaningfully higher than the market expects (or at least stops the bleeding).
- EBITDA guidance improves or costs show better control.
- Bookings/pipeline indicators inflect upward, suggesting next quarters could stabilize.
- Clear messaging on what changed versus last quarter—specific, measurable, and time-bound.
The key is credibility. Markets have a low tolerance for vague optimism in a shaky tape.
7) What could go wrong?
On the downside, a few things could pressure the stock further:
- Another guidance reset that implies longer weakness than expected.
- More deterioration in margins or higher costs that delay any profitability path.
- Weak customer metrics that point to churn risk or shrinking expansions.
- Evidence that demand softness is structural, not timing-related.
If management leans too hard on macro explanations without offering concrete operational fixes, investors may remain unwilling to re-rate the stock.
A practical way to think about Thursday’s report
This earnings release is essentially a referendum on whether Health Catalyst is entering a “quiet rebuilding phase” or slipping into a longer stagnation cycle.
- If the company stabilizes guidance and shows improving leading indicators, the stock could respond sharply because expectations are already low and positioning is cautious.
- If the company repeats the pattern—okay quarter, weak outlook—the market may treat it as confirmation that the business is still searching for a reliable growth engine.
Either way, the quarter will likely be decided less by one headline revenue number and more by what management says about demand, pipeline, and the profitability path in the next two to three quarters.
